Winfried A.
- Country
- Germany
- Department
- Medizinische Klinik II Onkologisches Zentrum
Research Overview
- A Phase I Study of TK-6302 in Patients with Advanced PRAME-Positive Solid Tumors Harboring the HLA-A*02:01 Allele
- Phase 1/2a Study of REGN10597 Alone or with Cemiplimab in Patients with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal Cell Carcinoma
- Phase III Randomized Trial of De-escalated MATRix Induction Therapy in Newly Diagnosed Primary CNS Lymphoma: Methotrexate, Cytarabine, Thiotepa, and Rituximab
Data & Insights
Has run more than one trial at 8 of 67 partner sites.
Specializations
Oncology Focus
The investigator specializes in treating solid organ tumors through innovative cellular therapy approaches. Their research encompasses chimeric antigen receptor T cell (CAR-T) treatments, particularly focusing on claudin 6 targeted therapies.
- Advanced Cell Therapies
- RNA-based Vaccine Development
- Immunotherapy Applications
Their work integrates novel therapeutic combinations including cell-based treatments and RNA vaccines.
Neuro-Oncology
The investigator has extensive experience in treating primary central nervous system lymphoma, with particular emphasis on diffuse large B-cell lymphoma (DLBCL) of the central nervous system.
- CNS Lymphoma Treatment
- Combination Chemotherapy Protocols
- Stem Cell Transplantation
Their research involves optimizing treatment protocols combining Methotrexate, Ara-C, Thiotepa, and Rituximab with high-dose therapy approaches.
Therapeutic Innovation
The investigator develops treatment strategies for rare and aggressive cancers, focusing on autologous stem cell transplantation and innovative drug combinations.
- Protocol Optimization
- Treatment De-escalation Strategies
- Novel Therapeutic Combinations
Their work aims to enhance treatment efficacy while optimizing therapeutic protocols for improved patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.